Results for
"[search-keyword]"
Sponsor content
224 result(s) found, displaying 11 to 20
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 17/12/2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 17/12/2023
-
Listed medicine compliance reportSunscreen continues to be permitted for supply. Batches released from 6 October 2023 must not contain HICC (4-(4-hydroxy-4-methylpentyl)-3-cyclohexene carboxaldehyde). (View full entry for advice on the safety of using this medicine.)
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29-07-2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29-07-2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 17-06-2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 17-06-2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 17-06-2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 17-06-2023
-
Cancellation by sponsorRequested by Arrow Pharma Pty Ltd